Nataša Jovic has led marketing strategies for retina products since the launch of Visudyne. Approved by the FDA in 2002, Visudyne was the first commercially available therapy to treat wet AMD.
Today, Jovic applies her scientific background and retina experience to lead marketing and commercial operations for RetinAI, a software company that supports R&D initiatives.
As a retina specialist, OIS podcast host Firas Rahhal, MD, wanted to know: what’s the deal with AI? How can it help me in my practice? Jovic provides insight.
At present, the FDA has approved over 500 AI-enabled medical devices, most of them in radiology and cardiology. Ophthalmology has seven. Those seven products, in addition to ancillary unregulated devices, she says, have the potential to streamline workflows, expedite clinical research, and generally assist in the clinical decision-making and care management.
Listen to the podcast today to discover:
[Press Play]
Resources
RetinAI https://www.retinai.com/
Natasa Jovic https://www.linkedin.com/in/natasa-jovic-b-sc-mba-8b40241/
Firas Rahhal, MD https://ois.net/firas-m-rahhal-md/
Artificial Intelligence and Machine Learning-Enabled Medical Devices https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices